After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral medication that is manufactured by Bristol Myers Squibb in New Jersey.
The U.S. FDA's approval Thursday of Bristol Myers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of ...
In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan ...
Bristol-Myers Squibb Co is facing a class-action lawsuit related to a $2 billion pension risk transfer deal made five years ...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...
Bristol-Myers Squibb delivered a significant earnings beat in Q2, driving shares up 20% since spring and boosting sector performance. Despite concerns about long-term EPS, strong Q2 results and ...
The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback